Showing results (21-30 of 174) with videos related to

Sort By:
Pageof 18
Expert Review of Hematology|July 20, 2019
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromesGuido Kobbe, Thomas Schroeder, Christina Rautenberg, et al.
International Journal of Environmental Research and Public Health|July 24, 2021
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?Annika Kasprzak, Jennifer Kaivers, Kathrin Nachtkamp, et al.
European Radiology|October 10, 2007
Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myelomaPatric Kröpil, Roland Fenk, Lars B Fritz, et al.
Leukemia Research|February 3, 2009
Impact on survival of different treatments for myelodysplastic syndromes (MDS)Kathrin Nachtkamp, Andrea Kündgen, Corinna Strupp, et al.
Hematological Oncology|June 21, 2007
Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantationThorsten Graef, Matthias Vaupel, Roland Fenk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 7, 2013
Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myelomaMark Korthals, Nina Sehnke, Ralf Kronenwett, et al.
Bone Marrow Transplantation|September 3, 2020
Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantationChristina Rautenberg, Anika Bergmann, Sabrina Pechtel, et al.
Leukemia Research|January 29, 2008
Unrelated umbilical cord blood transplantation as salvage treatment for engraftment failure following autologous stem cell transplantationRoland Fenk, Frank Neumann, Barbara Fenk, et al.
Experimental Hematology|September 20, 2006
Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myelomaRoland Fenk, Nadine Hieronimus, Ulrich Steidl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2011
The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameterMark Korthals, Nina Sehnke, Ralf Kronenwett, et al.
Pageof 18